Karyopharm Therapeutics Inc KPTI

NAS: KPTI | ISIN: US48576U1060   4/06/2025
4,340 USD (+2,12%)
(+2,12%)   4/06/2025

14 mei 2025 · Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting · Persbericht

12 mei 2025 · Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification · Persbericht

8 mei 2025 · Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 · Persbericht

1 mei 2025 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 april 2025 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 maart 2025 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 september 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 september 2024 · Karyopharm to Participate at Upcoming Investor Conferences · Persbericht

6 augustus 2024 · Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

1 augustus 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

31 juli 2024 · Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 · Persbericht

1 juli 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 juni 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 juni 2024 · Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates · Persbericht

29 mei 2024 · Karyopharm to Participate at the Jefferies Global Healthcare Conference · Persbericht

8 mei 2024 · Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference · Persbericht

8 mei 2024 · Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 · Persbericht

8 mei 2024 · Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

2 mei 2024 · Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 · Persbericht

1 mei 2024 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties